Navigation Links
Pixel Bridge Works With Anika Therapeutics to Launch New Website
Date:8/20/2008

Pixel Bridge, a Boston-based interactive marketing and Web development firm recently announced the launch of a new website for Anika Therapeutics - www.anikatherapeutics.com. Anika Therapeutics (NASDAQ: ANIK) develops products that address the fast-growing joint health, aesthetic, ophthalmic, veterinary and anti-adhesion markets. The company worked with Pixel Bridge to plan, design, develop and implement the new site.

Boston, MA (PRWEB) August 20, 2008 -- Pixel Bridge, a Boston-based interactive marketing and Web development firm recently announced the launch of a new website for Anika Therapeutics - www.anikatherapeutics.com. Anika Therapeutics (NASDAQ: ANIK) develops products that address the fast-growing joint health, aesthetic, ophthalmic, veterinary and anti-adhesion markets. The company worked with Pixel Bridge to plan, design, develop and implement the new site.

For more than 20 years, Anika has been a leader in developing therapies that leverage the benefits of hyaluronic acid (HA), a naturally occurring, biocompatible polymer found throughout the body that enhances joint function and coats, protects, cushions and lubricates soft tissues. The company is recognized worldwide as a provider of premium HA products that are effective, safe and long-lasting.

The company's new interactive property is version 2.0 of the site. The key underlying goals associated with the project were to:

  • Effectively educate site visitors about the company's products

  • Visually represent Anika as an innovative leader in its markets

  • Clearly articulate the company's value proposition and market differentiation

"Our goal in designing this site was to capture the energy and entrepreneurial spirit of the company, along with its long history of leadership in therapeutic technologies," said Scott Stephens, president of Pixel Bridge. "Anika has a broad range of therapies in the market and an impressive pipeline of innovative products under development. This demanded a site that was both comprehensive and easy to navigate and reflective of the company's vision for the future. The new website illustrates the company's uniqueness and we were proud to work with them on the project."

"Pixel Bridge worked with us on every step of this engagement - from concept to completion," notes Kevin Quinlan, CFO and Treasurer at Anika. "The firm's full range of capabilities made a potentially cumbersome project streamlined and relatively painless."

ABOUT ANIKA THERAPEUTICS
Headquartered in Bedford, Mass., Anika Therapeutics, Inc. develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair. These products are based on hyaluronic acid (HA), a naturally occurring, biocompatible polymer found throughout the body. Anika's products include ORTHOVISC(R), a treatment for osteoarthritis of the knee available internationally and marketed in the U.S. by DePuy Mitek; HYVISC(R), a treatment for equine osteoarthritis marketed in the U.S. by Boehringer Ingelheim Vetmedica, Inc.; the ELEVESS(TM) family of aesthetic dermatology products for facial wrinkles, scar remediation and lip augmentation marketed in the U.S. by Artes Medical, Inc.; AMVISC(R), AMVISC(R) Plus, STAARVISC(TM)-II and Shellgel(TM) injectable viscoelastic HA products for ophthalmic surgery; INCERT(R), an HA-based anti-adhesive for surgical applications; ORTHOVISC(R) mini a treatment for osteoarthritis targeting small joints and available in Europe; MONOVISC(TM) a single-injection osteoarthritis product based on our proprietary cross-linking technology and also available in Europe; and next generation products for joint health and aesthetic dermatology based on the Company's proprietary, chemically modified HA. For more information contact Anika at 781-457-9000 or visit www.anikatherapeutics.com.

ABOUT PIXEL BRIDGE
Pixel Bridge is a Boston-based interactive marketing and Web development firm that helps clients use the Internet to improve marketing, sales, and operations. Founded in 1999, the company seamlessly blends strategy, marketing, creative, and technology expertise to deliver highly effective websites, interactive marketing programs, and custom Internet applications. Pixel Bridge's client roster includes leading Boston-based companies such as The Boston Globe, Constant Contact, and Mac-Gray Corporation, as well as internationally recognized brands including Comcast, ITW, Krups, and Thomson. For more information contact Pixel Bridge at 617-542-5587 or visit www.pixelbridge.com.

Contacts
Pixel Bridge
Erin LaSpina
Tel: 617-542-5587
elaspina @ pixelbridge.com

2008 Pixel Bridge Inc, All Rights Reserved

###

Read the full story at http://www.prweb.com/releases/anikatherapeutics/newwebsite/prweb1226734.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related biology technology :

1. Siemens and Xintek Form Joint Venture to Develop Nanotechnology-Enabled Multi-Pixel X-ray Tubes
2. WorldHeart Enters into a Recapitalization Agreement and Receives Bridge Financing
3. New Fragment-based Drug Discovery Platform Announced Between IOTA Pharmaceuticals Ltd, Cambridge (UK), and Beactica AB, Uppsala (Sweden)
4. Rib-X Pharmaceuticals to Present at Cambridge Healthtech Institutes 2nd Annual Challenge of Antibacterial Development Conference
5. Lentigen Licenses Fundamental Lentiviral Vector Technology Patent From the University of Cambridge
6. WaferGen to Present at the Cambridge Health Institutes Fifth Annual Molecular Diagnostics Partnerships in Personalized Medicine Conference
7. NIST team proves bridge from conventional to molecular electronics possible
8. Antibody Engineering Company f-Star Opens Second Research Site in Cambridge, UK
9. Woodbridge Offers the Broadest Range of BioFoam(TM) Green Polyurethane Automotive Interior Applications
10. Cambridge Major Appoints Professor John Hartwig as Scientific Advisor
11. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Feb. 24, 2017  OncoSec Medical Incorporated ("OncoSec") ... will host a Key Opinion Leader event to highlight ... oral and poster presentation at the upcoming 2017 ASCO-SITC ... KOL event will be held in-person and via live ... / 9:00 AM PST at the Lotte New York ...
(Date:2/23/2017)... Calif. , Feb. 23, 2017  MIODx ... license for two key immunotherapy technologies from the ... technology provides a method to monitor a patient ... as PD-L1 and CTLA-4.  The second license extends ... a patient is likely to have an immune-related ...
(Date:2/23/2017)... (PRWEB) , ... February 23, ... ... Inc., announced today that in a published evaluation of multiple immunoassay-based threat ... U.S. Department of Energy Laboratory, PathSensors’ CANARY® biosensor threat detection technology was ...
(Date:2/23/2017)... 23, 2017 Aviva Systems Biology Corporation ... acquisition of GenWay Biotech Incorporated, a protein solutions ... product offering for both the research and diagnostic ... and enhance capabilities for both entities. GenWay,s 18 years ... will nicely complement ASB,s objective to become a ...
Breaking Biology Technology:
(Date:2/8/2017)... Feb. 7, 2017 Report Highlights ... 2021 from $8.3 billion in 2016 at a compound ... 2021. Report Includes - An overview of the ... trends, with data from 2015 and 2016, and projections ... Segmentation of the market on the basis of product ...
(Date:2/6/2017)... , Feb. 6, 2017 According ... security are driving border authorities to continue to ... reports there are 2143 Automated Border Control (ABC) ... currently deployed at more than 163 ports of ... 2013 to 2016 achieving a combined CAGR of ...
(Date:2/2/2017)... , Feb. 2, 2017  EyeLock LLC, a market ... new white paper " What You Should Know About ... of ensuring user authenticity is a growing concern. In ... of users. However, traditional authentication schemes such as username/password ... Biometric authentication offers an elegant solution to the ...
Breaking Biology News(10 mins):